Payment overview · 2025
General Payments
$125.62
5 reported records · 5 companies
Healthcare provider profile · identity verified
Allen Danforth Pettee, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ROCHESTER, NY · NPI 1780671511
Verified facts
What the public records show
CMS Open Payments records show Allen Danforth Pettee, M.D. received $125.62 in general payments during 2025 across 5 reported records.
Supernus Pharmaceuticals, Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.62 | 24.4% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $29.62 | 23.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.65 | 18.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $22.24 | 17.7% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.49 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.62 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | Octapharma USA, Inc., PFIZER INC. | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $20.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
142 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 821 | 148 |
| Donepezil Hcl | Donepezil Hcl | 364 | 63 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 321 | 58 |
| Pregabalin | Pregabalin | 262 | 44 |
| Topiramate | Topiramate | 249 | 45 |
| Memantine Hcl | Memantine Hcl | 236 | 42 |
| Levetiracetam | Levetiracetam | 231 | 39 |
| Sumatriptan Succinate | Sumatriptan Succinate | 228 | 46 |
| Dalfampridine Er | Dalfampridine | 213 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 44 |
| Aimovig Autoinjector | Erenumab-Aooe | 208 | 26 |
| Rizatriptan | Rizatriptan Benzoate | 145 | 29 |
| Clonazepam | Clonazepam | 143 | 29 |
| Nurtec Odt | Rimegepant Sulfate | 142 | 30 |
| Propranolol Hcl | Propranolol Hcl | 137 | 31 |
| Carbamazepine | Carbamazepine | 134 | 20 |
| Ubrelvy | Ubrogepant | 131 | 21 |
| Baclofen | Baclofen | 122 | 25 |
| Lamotrigine | Lamotrigine | 121 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 119 | 28 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 98 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 98 | 18 |
| Primidone | Primidone | 97 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 25 |
| Oxcarbazepine | Oxcarbazepine | 92 | 13 |
| Phenobarbital | Phenobarbital | 89 | suppressed |
| Carbamazepine Er | Carbamazepine | 71 | 11 |
| Teriflunomide | Teriflunomide | 68 | 11 |
| Trazodone Hcl | Trazodone Hcl | 64 | 16 |
| Methylphenidate Hcl | Methylphenidate Hcl | 63 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 58 | suppressed |
| Aubagio | Teriflunomide | 57 | suppressed |
| Modafinil | Modafinil | 57 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Diazepam | Diazepam | 54 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 54 | 11 |
| Methylprednisolone | Methylprednisolone | 53 | 38 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Amantadine | Amantadine Hcl | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Qulipta | Atogepant | 49 | 11 |
| Copaxone | Glatiramer Acetate | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 11 |
| Verapamil Er | Verapamil Hcl | 47 | suppressed |
| Mayzent | Siponimod | 46 | suppressed |
| Vimpat | Lacosamide | 44 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 41 | 11 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Keppra | Levetiracetam | 38 | suppressed |
| Lacosamide | Lacosamide | 38 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 38 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 38 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 38 | suppressed |
| Fingolimod | Fingolimod Hcl | 37 | suppressed |
| Prednisone | Prednisone | 36 | 16 |
| Dimethyl Fumarate | Dimethyl Fumarate | 35 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 35 | suppressed |
| Lamictal | Lamotrigine | 35 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 35 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 34 | suppressed |
| Clobazam | Clobazam | 34 | suppressed |
| Zonisamide | Zonisamide | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 27 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Ampyra | Dalfampridine | 24 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Zolmitriptan | Zolmitriptan | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Indomethacin | Indomethacin | 20 | suppressed |
| Reyvow | Lasmiditan Succinate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 11 | suppressed |
| Gabapentin Er | Gabapentin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Tysabri | Natalizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.62 · 5 records | Supernus Pharmaceuticals, Inc. | Gocovri, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, Qelbree, TRUDHESA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error